31,348 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Entropy Technologies LP

Entropy Technologies LP bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 31,348 shares of the medical research company’s stock, valued at approximately $2,069,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Crewe Advisors LLC purchased a new position in shares of Edwards Lifesciences during the first quarter valued at approximately $28,000. First Community Trust NA purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth $29,000. Webster Bank N. A. bought a new stake in shares of Edwards Lifesciences in the second quarter worth $39,000. Peoples Bank KS purchased a new stake in Edwards Lifesciences during the third quarter valued at $40,000. Finally, Versant Capital Management Inc lifted its holdings in Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on EW. Canaccord Genuity Group cut their price target on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a research note on Friday, October 25th. UBS Group reduced their target price on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Barclays reduced their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Finally, Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their target price for the company from $105.00 to $75.00 in a research report on Thursday, July 25th. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $75.67.

Insider Transactions at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,250 shares of company stock valued at $2,416,588 in the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

EW opened at $65.81 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.87 and a current ratio of 3.46. The stock has a market capitalization of $38.81 billion, a price-to-earnings ratio of 9.50, a PEG ratio of 3.72 and a beta of 1.12. The company has a fifty day moving average of $67.53 and a 200 day moving average of $76.65. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 earnings per share. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.